Figure 5.

Effect of EZH2 and HDAC2 inhibitors on FOXO1 protein expression in triple negative breast cancer cells. (A) MDA-MB-231 and (B) MDA-MB-436 cells were treated with vehicle (DMSO), GSK126, LBH589 or both GSK126 and LBH589 as indicated for 24 h. Cells were then harvested for western blot analysis using the indicated antibodies. ERK2 expression level was used as the protein loading control. Non-specific western blotting bands are indicated by *, a phenomenon observed in HeLa cells (http://www.cellsignal.com/products/primary-antibodies/akt-antibody/9272?N=4294956287&Ntt=akt&fromPage=plp). Similar results were obtained in two independent experiments. EZH2, enhancer of zeste 2 polycomb repressive complex 2 subunit; HDAC, histone deacetylase; DMSO, dimethyl sulfoxide; ERK2, extracellular signal-related kinase 2; AKT, protein kinase B; p-, phosphorylated; FOXO1, forkhead box O1; PTEN, phosphatase and tensin homolog.